Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Long-Acting cancer drug seeks to boost immune system against tumors

NCT ID NCT05081609

Ongoing Disease control Sponsor: Ascendis Pharma Oncology Division A/S Source: ClinicalTrials.gov ↗

Summary

This early-stage trial is testing a new long-acting immunotherapy drug called TransCon IL-2 β/γ in adults with advanced solid tumors that have spread or cannot be removed by surgery. The study aims to find safe doses and see if the drug, given alone or with other cancer treatments, can help control the cancer. It will enroll about 320 participants with various advanced cancers, including ovarian cancer, melanoma, lung cancer, and cervical cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Ascendis Pharma Investigational Site

    Los Angeles, California, 90048, United States

  • Ascendis Pharma Investigational Site

    Los Angeles, California, 90067, United States

  • Ascendis Pharma Investigational Site

    Springfield, Illinois, 62702, United States

  • Ascendis Pharma Investigational Site

    Louisville, Kentucky, 40202, United States

  • Ascendis Pharma Investigational Site

    Boston, Massachusetts, 02114, United States

  • Ascendis Pharma Investigational Site

    Morristown, New Jersey, 07960, United States

  • Ascendis Pharma Investigational Site

    New York, New York, 10032, United States

  • Ascendis Pharma Investigational Site

    Huntersville, North Carolina, 28078, United States

  • Ascendis Pharma Investigational Site

    Canton, Ohio, 44718, United States

  • Ascendis Pharma Investigational Site

    Cincinnati, Ohio, 45219, United States

  • Ascendis Pharma Investigational Site

    Oklahoma City, Oklahoma, 73104, United States

  • Ascendis Pharma Investigational Site

    Pittsburgh, Pennsylvania, 15232, United States

  • Ascendis Pharma Investigational Site

    Nashville, Tennessee, 37203, United States

  • Ascendis Pharma Investigational Site

    Richmond, Virginia, 23298, United States

  • Ascendis Pharma Investigational Site

    Adelaide, 5000, Australia

  • Ascendis Pharma Investigational Site

    Adelaide, 5042, Australia

  • Ascendis Pharma Investigational Site

    Brisbane, 04120, Australia

  • Ascendis Pharma Investigational Site

    Frankston, 3199, Australia

  • Ascendis Pharma Investigational Site

    Southport, 4215, Australia

  • Ascendis Pharma Investigational Site

    Toorak Gardens, 05065, Australia

  • Ascendis Pharma Investigational Site

    Waratah, 2298, Australia

  • Ascendis Pharma Investigational Site

    Wilrijk, 2610, Belgium

  • Ascendis Pharma Investigational Site

    Montreal, H4A 3J1, Canada

  • Ascendis Pharma Investigational Site

    Toronto, M4N 3M5, Canada

  • Ascendis Pharma Investigational Site

    Toronto, M5G 2C4, Canada

  • Ascendis Pharma Investigational Site

    Cuneo, 12100, Italy

  • Ascendis Pharma Investigational Site

    Florence, 50134, Italy

  • Ascendis Pharma Investigational Site

    Grosseto, 58100, Italy

  • Ascendis Pharma Investigational Site

    Lido di Camaiore, 55041, Italy

  • Ascendis Pharma Investigational Site

    Livorno, 57124, Italy

  • Ascendis Pharma Investigational Site

    Meldola, 47014, Italy

  • Ascendis Pharma Investigational Site

    Milan, 20133, Italy

  • Ascendis Pharma Investigational Site

    Milan, 20141, Italy

  • Ascendis Pharma Investigational Site

    Modena, 41124, Italy

  • Ascendis Pharma Investigational Site

    Roma, 00167, Italy

  • Ascendis Pharma Investigational Site

    Torino, 10126, Italy

  • Ascendis Pharma Investigational Site

    Turin, 10060, Italy

  • Ascendis Pharma Investigational Site

    Verona, 37134, Italy

  • Ascendis Pharma Investigational Site

    Krakow, 31-501, Poland

  • Ascendis Pharma Investigational Site

    Poznan, 60693, Poland

  • Ascendis Pharma Investigational Site

    Warsaw, 02-781, Poland

  • Ascendis Pharma Investigational Site

    Singapore, 119228, Singapore

  • Ascendis Pharma Investigational Site

    Singapore, 217562, Singapore

  • Ascendis Pharma Investigational Site

    Seoul, Songpa-gu, 05505, South Korea

  • Ascendis Pharma Investigational Site

    Seongnam-si, 13620, South Korea

  • Ascendis Pharma Investigational Site

    Seoul, 03080, South Korea

  • Ascendis Pharma Investigational Site

    Seoul, 03722, South Korea

  • Ascendis Pharma Investigational Site

    Seoul, 06231, South Korea

  • Ascendis Pharma Investigational Site

    Seoul, 06351, South Korea

  • Ascendis Pharma Investigational Site

    Barcelona, 08023, Spain

  • Ascendis Pharma Investigational Site

    Barcelona, 08028, Spain

  • Ascendis Pharma Investigational Site

    Barcelona, 08035, Spain

  • Ascendis Pharma Investigational Site

    L'Hospitalet de Llobregat, 08908, Spain

  • Ascendis Pharma Investigational Site

    Madrid, 28006, Spain

  • Ascendis Pharma Investigational Site

    Madrid, 28027, Spain

  • Ascendis Pharma Investigational Site

    Madrid, 28040, Spain

  • Ascendis Pharma Investigational Site

    Madrid, 28041, Spain

  • Ascendis Pharma Investigational Site

    Madrid, 28050, Spain

  • Ascendis Pharma Investigational Site

    Málaga, 29010, Spain

  • Ascendis Pharma Investigational Site

    Murcia, 30120, Spain

  • Ascendis Pharma Investigational Site

    Oviedo, 33011, Spain

  • Ascendis Pharma Investigational Site

    Pamplona, 31008, Spain

  • Ascendis Pharma Investigational Site

    Seville, 41009, Spain

  • Ascendis Pharma Investigational Site

    Seville, 41014, Spain

  • Ascendis Pharma Investigational Site

    Valencia, 46009, Spain

  • Ascendis Pharma Investigational Site

    Valencia, 46014, Spain

  • Ascendis Pharma Investigational Site

    Taipei, 10002, Taiwan

  • Ascendis Pharma Investigational Site

    Taipei, 11259, Taiwan

Conditions

Explore the condition pages connected to this study.

2L+ CERVICAL CANCER ADVANCED SOLID TUMOR LOCALLY ADVANCED SOLID TUMOR METASTATIC SOLID TUMOR NEOADJUVANT MELANOMA NEOADJUVANT NON-SMALL CELL LUNG CANCER PLATINUM-RESISTANT OVARIAN CANCER POST ANTI-PD-(L)1 NON-SMALL CELL LUNG CANCER POST ANTI-PD-(L)1 SMALL CELL LUNG CANCER POST ANTI-PD-1 MELANOMA SECOND OR THIRD LINE (2L/3L) CERVICAL CANCER THIRD LINE OR LATER (3L+) HER2+ BREAST CANCER THIRD-LINE OR LATER (3L+) PLATINUM-RESISTANT OVARIAN CANCER (PROC)